Sheng L, Bhalla R (2024) Biomarkers and Target-Specific Small-Molecule drugs in alzheimer’s diagnostic and therapeutic research: from amyloidosis to tauopathy. Neurochem Res 49:2273–2302

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO WHO (2018) The global dementia observatory reference guide. In. World Health Organization

Wong-Guerra M, Montano-Peguero Y, Ramírez-Sánchez J, Alfonso EG, Hernández-Enseñat D, Isaac YA, Padrón-Yaquis AS, da Rocha JBT, Fonseca-Fonseca LA, Núñez-Figueredo Y (2024) Effect of JM-20 on Age-Related cognitive impairment in mice. Neurochem Res 50:8

Article  PubMed  Google Scholar 

Liu Y, Meng X-K, Shao W-z, Liu Y-q, Tang C, Deng S-s, Tang C-f, Zheng L, Guo W (2024) miR-34a/TAN1/CREB Axis engages in alleviating oligodendrocyte trophic Factor-Induced myelin repair function and Astrocyte-Dependent neuroinflammation in the early stages of alzheimer’s disease: the Anti-Neurodegenerative effect of treadmill exercise. Neurochem Res 49:1105–1120

Article  CAS  PubMed  Google Scholar 

Fratiglioni L, De Ronchi D, Agüero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drugs Aging 15:365–375

Article  CAS  PubMed  Google Scholar 

Gao Y, Tan L, Yu J-T, Tan L (2018) Tau in alzheimer’s disease: mechanisms and therapeutic strategies. Curr Alzheimer Res 15:283–300

Article  CAS  PubMed  Google Scholar 

Caraci F, Copani A, Nicoletti F, Drago F (2010) Depression and alzheimer’s disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626:64–71

Article  CAS  PubMed  Google Scholar 

Cheng F, Chang H, Yan F, Yang A, Liu J, Liu Y (2020) Agomelatine attenuates isoflurane-induced inflammation and damage in brain endothelial cells. Drug Des Devel Ther:5589–5598

Minhas PS, Latif-Hernandez A, McReynolds MR, Durairaj AS, Wang Q, Rubin A, Joshi AU, He JQ, Gauba E, Liu L (2021) Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature 590:122–128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caruso G, Grasso M, Fidilio A, Torrisi SA, Musso N, Geraci F, Tropea MR, Privitera A, Tascedda F, Puzzo D, Salomone S, Drago F, Leggio GM, Caraci F (2021) Antioxidant activity of fluoxetine and vortioxetine in a Non-Transgenic animal model of alzheimer’s disease. Front Pharmacol 12:809541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kennedy SH, Rizvi SJ (2010) Agomelatine in the treatment of major depressive disorder. CNS Drugs 24:479–499

Article  CAS  PubMed  Google Scholar 

Millan MJ, Brocco M, Gobert A, Dekeyne A (2005) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 177:448–458

Article  CAS  PubMed  Google Scholar 

Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003) The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-Hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954–964

Article  CAS  PubMed  Google Scholar 

Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E (2014) Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 171:3604–3619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ju Y, Ou W, Chen H, Yang L, Long Y, Liang H, Xi Z, Huang M, Chen W, Lv G, Shao F, Liu B, Liu J, Li Z, Liao M, Liang W, Yao Z, Zhang Y, Li L (2025) Agomelatine as adjunctive therapy with ssris or snris for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial. BMC Med 23:137

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR (1993) Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 46:45–49

Article  CAS  PubMed  Google Scholar 

Li H-H, Yao X-Y, Tao S, Sun X, Li P-p, Li X-x, Liu Z-L, Ren C (2021) Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease. Behav Neurol 2021:5533827

Cankara FN, Günaydın C, Çelik ZB, Şahin Y, Pekgöz Ş, Erzurumlu Y, Gülle K (2021) Agomelatine confers neuroprotection against cisplatin-induced hippocampal neurotoxicity. Metab Brain Dis 36:339–349

Article  CAS  PubMed  Google Scholar 

Ballester P, Martínez MJ, Inda M-d-M, Javaloyes A, Richdale AL, Muriel J, Belda C, Toral N, Morales D, Fernández E (2019) Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and comorbid intellectual disability. J Psychopharmacol 33:1395–1406

Article  PubMed  Google Scholar 

Wang S, Li C, Kang X, Su X, Liu Y, Wang Y, Liu S, Deng X, Huang H, Li T, Lu D, Cai W, Lu Z, Wei L, Lu T (2024) Agomelatine promotes differentiation of oligodendrocyte precursor cells and preserves white matter integrity after cerebral ischemic stroke. J Cereb Blood Flow Metab 44:1487–1500

Article  CAS  PubMed  Google Scholar 

Firdoos S, Dai R, Younas Z, Shah FA, Gul M, Rasheed M (2024) Agomelatine-loaded nanostructured lipid carriers alleviate neuropathic pain in rats by Nrf2/HO-1 signalling pathway. Clin Exp Pharmacol Physiol 51:e13922

Article  CAS  PubMed  Google Scholar 

Fatouh AM, EA H, Abdelbary A (2017) Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther 11:1815–1825

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orgeta V, Tabet N, Nilforooshan R, Howard R (2017) Efficacy of antidepressants for depression in alzheimer’s disease: systematic review and Meta-Analysis. J Alzheimers Dis 58:725–733

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ilieva K, Tchekalarova J, Atanasova D, Kortenska L, Atanasova M (2019) Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of alzheimer’s disease in male rats. Horm Behav 107:11–19

Article  CAS  PubMed  Google Scholar 

Ilieva K, Atanasova M, Atanasova D, Kortenska L, Tchekalarova J (2021) Chronic agomelatine treatment alleviates icvAβ-induced anxiety and depressive-like behavior through affecting Aβ metabolism in the hippocampus in a rat model of alzheimer’s disease. Physiol Behav 239:113525

Article  CAS  PubMed  Google Scholar 

Karaiskos D, Katirtzoglou E, Papadimitriou GN, Pappa D, Politis A, Siarkos K, Tzavellas E (2014) EPA-1197 – Agomelatine for treating apathy in alzheimer’s disease. Eur Psychiatry 29:1–1

Google Scholar 

Cao Y, Wang F, Wang Y, Long J (2021) Agomelatine prevents macrophage infiltration and brain endothelial cell damage in a stroke mouse model. Aging (Albany N Y) 13:13548–13559

CAS  Google Scholar 

Altınyazar V, Kiylioglu N (2016) Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature. Therapeutic Adv Psychopharmacol 6:263–268

Article  Google Scholar 

Bergantin LB (2020) The interactions between alzheimer’s disease and major depression: role of Ca(2+) channel blockers and Ca(2+)/cAMP signalling. Curr Drug Res Reviews 12:97–102

Article  CAS  Google Scholar 

Hu Y, Fang X, Wang J, Ren T-T, Zhao Y-Y, Dai J-F, Qin X-Y, Lan R (2022) Astragalin attenuates AlCl3/D-galactose-induced aging-like disorders by inhibiting oxidative stress and neuroinflammation. Neurotoxicology 91:60–68

Article  CAS  PubMed  Google Scholar 

Chiroma SM, Mohd Moklas MA, Mat Taib CN, Baharuldin MTH, Amon Z (2018) d-galactose and aluminium chloride induced rat model with cognitive impairments. Biomed Pharmacother 103:1602–1608

Article  CAS  PubMed  Google Scholar 

Chiroma SM, Hidayat Baharuldin MT, Mat Taib CN, Amom Z, Jagadeesan S, Adenan MI, Mohd Moklas MA (2019) Protective effect of Centella asiatica against D-galactose and aluminium chloride induced rats: behavioral and ultrastructural approaches. Biomed Pharmacother 109:853–864

Article  CAS  PubMed  Google Scholar